EpicephIn Vials

Composition

EPICEPHIN 250 mg I.M.

Dry substance: Ceftriaxone disodium hemi heptahydrate 298.2 mg equivalent to 250 mg ceftriaxone per vial.

Solvent: Lidocaine hydrochloride monohydrate 21.33 mg equivalent to 20 mg lidocaine hydrochloride, water for injection q.s. 2 ml of solution.

EPICEPHIN 250 mg I.V.

Dry substance: Ceftriaxone disodium hemi heptahydrate 298.2 mg equivalent to 250 mg ceftriaxone per vial.

Solvent: Water for injection 5 ml.

EPICEPHIN 500 mg I.M.

Dry substance: Ceftriaxone disodium hemi heptahydrate 596.5 mg equivalent to 500 mg ceftriaxone per vial.

Solvent: Lidocaine hydrochloride monohydrate 21.33 mg equivalent to 20 mg lidocaine hydrochloride, water for injection q.s. 2 ml of solution.

EPICEPHIN 500 mg I.V.

Dry substance: Ceftriaxone disodium hemi heptahydrate 596.5 mg equivalent to 500 mg ceftriaxone per vial.

Solvent: Water for injection 5 ml.

EPICEPHIN 1 g I.M.

Dry substance: Ceftriaxone 1 g as disodium hemi heptahydrate per vial.

Solvent: Lidocaine hydrochloride monohydrate 37.3 mg equivalent to 35 mg lidocaine hydrochloride, water for injection q.s. 3.5 ml of solution.

EPICEPHIN 1 g I.V.

Dry substance: Ceftriaxone 1 g as disodium hemi heptahydrate per vial.

Solvent: Water for injection 10 ml.

EPICEPHIN 2 g I.V.

Dry substance: Ceftriaxone disodium hemi heptahydrate 2386.0 mg equivalent to 2000 mg ceftriaxone per vial.

Solvent: Water for injection 10 ml.

Therapeutic Indications

EPICEPHIN is indicated for the treatment of the following infections in Adults and Children including term neonates (from birth):

Bacterial meningitis.

Community acquired pneumonia.

Hospital acquired pneumonia.

Acute otitis media.

Intra-abdominal infections.

Complicated urinary tract infections (including pyelonephritis).

Infections of bones and joints.

Complicated skin and soft tissue infections.

Gonorrhoea.

Syphilis.

Bacterial endocarditis.

EPICEPHIN may be used:

For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults.

For treatment of disseminated Lyme borreliosis (early [Stage II] and late [Stage III]) in adults and children including neonates from 15 days of age.

For Pre-operative prophylaxis of surgical site infections.

In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

EPICEPHIN should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum. (see Warnings and Precaution).

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.